For screening of tumors with a known low frequency of NTRK fusions where NGS is not routinely performed (e.g., colon cancer), Penault‐Llorca and colleagues recommend pan‐TRK immunohistochemistry (IHC) and, if positive, NGS.22 This evidence concerns the gene TPM3 and colonic neoplasm.